Moa Technology ("Moa"), an agricultural biotechnology company focused on discovering novel mode of action herbicides, announces a £22.2 million Series C financing round, co-led by Oxford Science ...
The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for its gout drug, dotinurad.
Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro (zidesamtinib) having gained US approval in ROS1-positive non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results